Efficacy of naratriptan tablets in the acute treatment of migraine:: A dose-ranging study

被引:41
作者
Havanka, H [1 ]
Dahlöf, C [1 ]
Pop, PHM [1 ]
Diener, HC [1 ]
Winter, P [1 ]
Whitehouse, H [1 ]
Hassani, H [1 ]
机构
[1] Lansi Pohjan Keskussairaala, Neurol Poliklin, Kemi 94100, Finland
关键词
naratriptan; migraine; sumatriptan; headache;
D O I
10.1016/S0149-2918(00)80068-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: This study sought to compare the efficacy of several doses of naratriptan tablets with that of sumatriptan tablets and placebo in the acute treatment of a single migraine attack. Methods: This was a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study. Patients received either naratriptan tablets (1, 2.5, 5, 7.5, or 10 mg), sumatriptan tablets (100 mg), or placebo. Results: A total of 643 patients took part in the study. Two hours after dosing, headache relief was reported by significantly more patients treated with any dose of naratriptan (52%-69%) or sumatriptan (60%) than with placebo (31%) (P < 0.05). Four hours after dosing, headache relief was reported by significantly more patients treated with any dose of naratriptan (63%-80%) or sumatriptan (80%) than with placebo (39%) and by significantly more patients treated with sumatriptan 100 mg (80%) than with naratriptan 1 mg (64%), 2.5 mg (63%), or 5 mg (65%) (P < 0.05). Twenty-four-hour overall efficacy (headache relief maintained through 24 hours postdose with no worsening, no use of rescue medication, and no recurrence) was reported by more patients treated with any dose of naratriptan (39%-58%) or sumatriptan (44%) than with placebo (22%). Headache recurrence was reported in 17% to 32% of naratriptan-treated patients, 44% of sumatriptan-treated patients, and 36% of placebo recipients. The overall incidence of adverse events was similar in patients treated with naratriptan I mg (20%), naratriptan 2.5 mg (21%), and placebo (23%). For naratriptan 5, 7.5, and 10 mg, the incidence of adverse events was 32%, 37%, and 35%, respectively and for sumatriptan 100 mg it was 26%. Conclusions: Our results suggest that the 2.5-mg dose of naratriptan tablets offers the optimal efficacy-to-tolerability ratio at the dose range between 1 and 10 mg. Although naratriptan 2.5 mg was less effective than sumatriptan 100 mg at 4 hours after dosing, the 2 medications showed similar efficacy at 24 hours.
引用
收藏
页码:970 / 980
页数:11
相关论文
共 14 条
  • [1] [Anonymous], 1991, Eur Neurol, V31, P314
  • [2] FERRARI MD, 1991, NEW ENGL J MED, V325, P316
  • [3] FUSEAU E, 1997, CEPHALALGIA, V17, P417
  • [4] Evaluation of the long-term safety and efficacy of 311C90 in the treatment of migraine
    Geraud, GEA
    [J]. EUROPEAN NEUROLOGY, 1996, 36 : 24 - 27
  • [5] *GLAX WELLC, S2WB3002 GLAX WELLC
  • [6] GOBEL H, 1997, CEPHALALGIA, V17, P426
  • [7] Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study
    Klassen, A
    Elkind, A
    Asgharnejad, M
    Laurenza, A
    [J]. HEADACHE, 1997, 37 (10): : 640 - 645
  • [8] Naratriptan is effective and well tolerated in the acute treatment of migraine - Results of a double-blind, placebo-controlled, crossover study
    Mathew, NT
    Asgharnejad, M
    Peykamian, M
    Laurenza, A
    [J]. NEUROLOGY, 1997, 49 (06) : 1485 - 1490
  • [9] MCCULLAGH P, 1983, GEN LINEAR MODELS, P101
  • [10] MEASURING THE FUNCTIONAL STATUS AND WELL-BEING OF PATIENTS WITH MIGRAINE HEADACHE
    OSTERHAUS, JT
    TOWNSEND, RJ
    GANDEK, B
    WARE, JE
    [J]. HEADACHE, 1994, 34 (06): : 337 - 343